1. Home
  2. GBDC vs ARQT Comparison

GBDC vs ARQT Comparison

Compare GBDC & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBDC
  • ARQT
  • Stock Information
  • Founded
  • GBDC 2009
  • ARQT 2016
  • Country
  • GBDC United States
  • ARQT United States
  • Employees
  • GBDC N/A
  • ARQT N/A
  • Industry
  • GBDC Finance: Consumer Services
  • ARQT Biotechnology: Pharmaceutical Preparations
  • Sector
  • GBDC Finance
  • ARQT Health Care
  • Exchange
  • GBDC Nasdaq
  • ARQT Nasdaq
  • Market Cap
  • GBDC 3.7B
  • ARQT 3.3B
  • IPO Year
  • GBDC 2010
  • ARQT 2020
  • Fundamental
  • Price
  • GBDC $13.60
  • ARQT $28.01
  • Analyst Decision
  • GBDC Buy
  • ARQT Strong Buy
  • Analyst Count
  • GBDC 3
  • ARQT 7
  • Target Price
  • GBDC $15.00
  • ARQT $22.17
  • AVG Volume (30 Days)
  • GBDC 1.5M
  • ARQT 3.1M
  • Earning Date
  • GBDC 11-18-2025
  • ARQT 10-28-2025
  • Dividend Yield
  • GBDC 11.83%
  • ARQT N/A
  • EPS Growth
  • GBDC 4.12
  • ARQT N/A
  • EPS
  • GBDC 1.42
  • ARQT N/A
  • Revenue
  • GBDC $870,777,000.00
  • ARQT $317,929,000.00
  • Revenue This Year
  • GBDC $23.63
  • ARQT $85.27
  • Revenue Next Year
  • GBDC N/A
  • ARQT $30.70
  • P/E Ratio
  • GBDC $9.55
  • ARQT N/A
  • Revenue Growth
  • GBDC 20.16
  • ARQT 129.21
  • 52 Week Low
  • GBDC $12.68
  • ARQT $9.19
  • 52 Week High
  • GBDC $16.01
  • ARQT $28.96
  • Technical
  • Relative Strength Index (RSI)
  • GBDC 38.76
  • ARQT 71.06
  • Support Level
  • GBDC $13.44
  • ARQT $22.26
  • Resistance Level
  • GBDC $14.14
  • ARQT $24.39
  • Average True Range (ATR)
  • GBDC 0.23
  • ARQT 1.46
  • MACD
  • GBDC -0.05
  • ARQT 0.21
  • Stochastic Oscillator
  • GBDC 20.55
  • ARQT 85.67

About GBDC Golub Capital BDC Inc.

Golub Capital BDC Inc is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and capital appreciation by investing in senior secured and one-stop loans in United States middle-market companies. It also invests in the second lien and subordinated loans, warrants, and minority equity securities in United States middle-market companies. The company generally invests in securities that have been rated below investment grade by independent rating agencies or that would be rated below investment grade if rated. Maximum investment is done in USA and Canadian Companies, with maximum profit earned from those countries.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Share on Social Networks: